Sanofi gets US FDA OK for talking injection device

- Last updated on GMT

Related tags: Asthma

Sanofi gets US FDA OK for talking injection device
Sanofi has received US FDA approval for an auto-injector that gives audio and visual cues to assist in the injection process.

The product - Auvi-Q (epinephrine injection, USP) – is used for the treatment of allergic reactions in people who are at risk for or have a history of anaphylaxis.

The idea is that under such life-threatening circumstances the device talks users or caregivers through each step of the injection process with audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete.

Sanofi licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.

Bryan Downey, Vice President, Auvi-Q, Sanofi US, said: “With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process,”

The French drugmaker licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...